Related references
Note: Only part of the references are listed.Comparative Survival and Cost-Effectiveness of Advanced Therapies for End-Stage Heart Failure
Elisa F. Long et al.
CIRCULATION-HEART FAILURE (2014)
Clinical practice guideline on diagnosis and treatment of hyponatraemia
Goce Spasovski et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Diuretic Use in Heart Failure and Outcomes
T. G. von Lueder et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
John J. V. McMurray et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2012)
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
John J. V. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study
Jalal K. Ghali et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
Significance of hyponatremia in heart failure
Luca Bettari et al.
HEART FAILURE REVIEWS (2012)
Hyponatremia and Long-Term Outcomes in Chronic Heart Failure-An Observational Study From the Duke Databank for Cardiovascular Diseases
Luca Bettari et al.
JOURNAL OF CARDIAC FAILURE (2012)
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
Rafael Lozano et al.
LANCET (2012)
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
John J. V. McMurray et al.
EUROPEAN HEART JOURNAL (2012)
Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: Analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Trials
Peter S. Pang et al.
AMERICAN HEART JOURNAL (2011)
Effects of Tolvaptan on Volume Overload in Japanese Patients with Heart Failure: Results of a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study
Masunori Matsuzaki et al.
CARDIOVASCULAR DRUGS AND THERAPY (2011)
Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study)
Masunori Matsuzaki et al.
CARDIOVASCULAR DRUGS AND THERAPY (2011)
Phase III Clinical Pharmacology Study of Tolvaptan
Takayuki Inomata et al.
CARDIOVASCULAR DRUGS AND THERAPY (2011)
Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study
Doron Aronson et al.
EUROPEAN JOURNAL OF HEART FAILURE (2011)
Renal Effects of Conivaptan, Furosemide, and the Combination in Patients With Chronic Heart Failure
Steven R. Goldsmith et al.
JOURNAL OF CARDIAC FAILURE (2011)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Tolvaptan Monotherapy Compared to Furosemide and the Combination of Tolvaptan and Furosemide in Patients With Heart Failure and Systolic Dysfunction
James E. Udelson et al.
JOURNAL OF CARDIAC FAILURE (2011)
Heart Failure 3 Implantable cardioverter defibrillators and cardiac resynchronisation therapy
Johannes Holzmeister et al.
LANCET (2011)
Vasopressin Receptor Antagonists for the Treatment of Hyponatremia: Systematic Review and Meta-analysis
Benaya Rozen-Zvi et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2010)
Executive Summary: Heart Disease and Stroke Statistics-2010 Update A Report From the American Heart Association
Donald Lloyd-Jones et al.
CIRCULATION (2010)
Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience
Juan Carlos Q. Velez et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia
John J. Finley et al.
CIRCULATION (2008)
Efficacy and Safety of the Vasopressin V1A/V2-Receptor Antagonist Conivaptan in Acute Decompensated Heart Failure: A Dose-Ranging Pilot Study
Steven R. Goldsmith et al.
JOURNAL OF CARDIAC FAILURE (2008)
Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction An International, Multicenter, Randomized, Placebo-Controlled Trial
James E. Udelson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial
Mihai Gheorghiade et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure - The EVEREST clinical status trials
Mihai Gheorghiade et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effects of oral tolvaptan in patients hospitalized for worsening heart failure - The EVEREST outcome trial
Marvin A. Konstam et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia
Robert W. Schrier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints
Roger M. Harbord et al.
STATISTICS IN MEDICINE (2006)
Aquaretic efect of Lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients
WT Abraham et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
LC Costello-Boerrigter et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2006)
Diuretic usage in heart failure: a continuing conundrum in 2005
S Gupta et al.
EUROPEAN HEART JOURNAL (2005)
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure - A randomized controlled trial
M Gheorghiade et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure
JE Udelson et al.
CIRCULATION (2001)
Share Paper
